Posters and mini-orals include another VEGF bispecific.
ApexOnco Front Page
Recent articles
Interius, one of the most advanced players, will cost $350m.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The players are vying in the CD19 x CD20 Car-T arena.
